New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment
Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement LONDON --(BUSINESS WIRE)--Jan. 17, 2019-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate studies...Read More
